FDA Approves Second TTR Stabilizer for Cardiac Amyloidosis

77 Views

Emedinexus 28 April 2025

The FDA has approved BridgeBio’s acoramidis (Attruby), a transthyretin (TTR) stabilizer, for treating cardiac amyloidosis (ATTR-CM). This marks the second drug approved for the condition. Other biopharma companies are also developing treatments for this rare heart disease and anticipate entering the market soon.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.